Johns Hopkins ABX Guide
Baloxavir
INDICATIONS
FDA
FDA
- Treatment of uncomplicated influenza, ages ≥ 5 years with symptoms < 48 hours.
- Limitations of use:
- Consider susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir, as viruses change over time, and virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.
- Baloxavir carries the FDA label for individuals at high risk (based on the Capstone 2 trial), unlike neuraminidase inhibitors (e.g., oseltamivir).
- Limitations of use:
- Post-exposure prophylaxis (PEP) in patients ≥5 years
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 8, 2026
Citation
Dzintars, Kate, and Paul G Auwaerter. "Baloxavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/0/Baloxavir.
Dzintars K, Auwaerter PG. Baloxavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/0/Baloxavir. Accessed March 24, 2026.
Dzintars, K., & Auwaerter, P. G. (2026). Baloxavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/0/Baloxavir
Dzintars K, Auwaerter PG. Baloxavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 March 24]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/0/Baloxavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Baloxavir
ID - 540707
A1 - Dzintars,Kate,Pharm.D., BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2026/03/08/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540707/0/Baloxavir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
